Synplogen

Kobe, Japan· Est. 2017

A synthetic biology company providing precision long-chain DNA synthesis and integrated development services for gene therapy products.

synplogen.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

Private Company

Funding information not available

AI Company Overview

A synthetic biology company providing precision long-chain DNA synthesis and integrated development services for gene therapy products.

Genetic DiseasesOncology

Technology Platform

OGAB™ technology enables precise assembly of up to 50 DNA fragments to synthesize long-strand DNA (few kb to over 100 kb) with high success rates, while Combinatorial-OGAB™ creates diverse DNA libraries with thousands of variants.

Opportunities

Growth opportunities include expanding service offerings for mRNA therapeutics, leveraging Japan's growing gene therapy ecosystem, and potentially developing proprietary gene therapy assets using their platform technology.

Risk Factors

Key risks include dependence on the gene therapy sector's growth, competition from larger international DNA synthesis and CDMO companies, and potential technological disruption in DNA synthesis methods.

Competitive Landscape

Competes with DNA synthesis companies (Twist Bioscience, GenScript) and gene therapy CDMOs; differentiates through proprietary long-DNA synthesis technology combined with specialized gene therapy development services in the Japanese market.

More companies in Japan →